Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic acquisition propels Lilly’s quest to pioneer advanced encapsulated cell therapies, prominently spotlighting the SIG-002 treatment for type 1 diabetes. Driven by its mission to “Make life better,” Lilly’s acquisition is […]
Pharmaceutical giant Eli Lilly and Company (Lilly) has announced its definitive agreement to acquire Nasdaq-listed biopharma innovator Sigilon Therapeutics, in a move set to significantly impact the biopharmaceutical industry and the treatment of chronic diseases. The deal, valued at approximately $309.6 million excluding shares held by Lilly, not only promises to reshape the landscape of […]
Mylan and Biocon have secured approval from the US Food and Drug Administration (FDA) for Semglee (insulin glargine injection) in vial and pre-filled pen presentations to regulate high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. According to Mylan, Semglee has an identical amino acid sequence […]
Pandion Therapeutics has bagged a $795 million worth license and collaboration deal with Japanese pharma company Astellas Pharma for the research, development, and commercialization of locally acting immunomodulators targeting autoimmune diseases of the pancreas. The collaboration will bring together the modular biologics and functional immunology expertise of Cambridge-based biotech company and Astellas Pharma’s advanced therapeutics […]
Xeris Pharmaceuticals, a specialty pharmaceutical company based in Chicago, has announced the commencement of dosing in its phase 2 clinical trial. The trial aims to evaluate its ready-to-use, room temperature-stable glucagon in patients with Type 1 diabetes who suffer from exercise-induced hypoglycemia (EIH). This is a critical step for the company as it looks to […]